Want to see TSE:ADK full AI Analyst Report?
Top Page
Diagnos
(ADK)
Select Model
Select Model
Rating:47Neutral
Price Target:
C$0.46
▲(11.71% Upside)
Action:Reiterated
Date:08/27/26
The score is weighed down primarily by weak financial performance (contracting revenue, sizable losses, and sustained cash burn with a fragile balance sheet) and limited valuation support due to unprofitability. Technicals are the main positive, with a strong uptrend and positive MACD, but overbought RSI/Stoch readings increase reversal risk.
Positive Factors
Diagnostic imaging focus
A specialized diagnostic imaging and software focus gives Diagnos exposure to healthcare information services and potential demand for technology that supports disease detection and clinical decision-making.
Negative Factors
Sharp revenue contraction
The steep multi-year revenue decline indicates shrinking commercial scale and weak demand conversion, reducing operating leverage and making it harder for the company to support product investment or reach breakeven.
Read all positive and negative factors
Positive Factors
Negative Factors
Diagnostic imaging focus
A specialized diagnostic imaging and software focus gives Diagnos exposure to healthcare information services and potential demand for technology that supports disease detection and clinical decision-making.
Read all positive factors
Diagnos (ADK) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$57.20M
Dividend YieldN/A
Average Volume (3M)368.58K
Price to Earnings (P/E)―
Beta (1Y)0.69
Revenue Growth-36.92%
EPS Growth13.03%
CountryCA
Employees16
SectorGeneral
Sector StrengthN/A
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.04
Shares Outstanding120,412,550
10 Day Avg. Volume301,407
30 Day Avg. Volume368,580
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)43.19
Price to Sales (P/S)453.09
P/FCF Ratio-7.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Diagnos Business Overview & Revenue Model
Company Description
DIAGNOS Inc. is a technology firm that delivers software-based services across a broad international footprint, encompassing Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica. A significant portion of its operations ...
How the Company Makes Money
null...
Diagnos Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
10
Very Negative
| Breakdown | Mar 2026 | Mar 2025 | Jun 2023 | Jun 2022 | Mar 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 65.48K | 103.80K | 170.16K | 267.07K | 331.52K |
| Gross Profit | -119.45K | -943.56K | 35.80K | -347.53K | -473.45K |
| EBITDA | -4.13M | -3.56M | -2.45M | -2.45M | -1.93M |
| Net Income | -4.56M | -4.29M | -3.12M | -2.05M | -3.38M |
Balance Sheet | |||||
| Total Assets | 2.39M | 3.64M | 663.79K | 1.95M | 2.43M |
| Cash, Cash Equivalents and Short-Term Investments | 1.93M | 3.24M | 219.01K | 1.36M | 1.87M |
| Total Debt | 1.40M | 3.07M | 3.19M | 471.68K | 337.55K |
| Total Liabilities | 1.70M | 3.40M | 3.72M | 818.19K | 614.78K |
| Stockholders Equity | 686.90K | 233.11K | -3.05M | 1.13M | 1.82M |
Cash Flow | |||||
| Free Cash Flow | -4.01M | -3.65M | -2.16M | -1.40M | -2.66M |
| Operating Cash Flow | -4.00M | -3.64M | -2.15M | -1.36M | -2.64M |
| Investing Cash Flow | 1.56M | -3.11M | -14.02K | 262.93K | -759.98K |
| Financing Cash Flow | 2.66M | 6.62M | 2.08M | 882.82K | 3.83M |
Diagnos Technical Analysis
Positive
0.41
Price Trends
0.33
Positive
0.27
Positive
0.29
Positive
Market Momentum
0.05
Negative
70.78
Negative
65.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ADK, the sentiment is Positive. The current price of 0.41 is below the 20-day moving average (MA) of 0.43, above the 50-day MA of 0.33, and above the 200-day MA of 0.29, indicating a bullish trend. The MACD of 0.05 indicates Negative momentum. The RSI at 70.78 is Negative, neither overbought nor oversold. The STOCH value of 65.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:ADK.
Diagnos Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
47 Neutral | C$57.20M | -11.50 | 9999.00% | ― | -36.92% | 13.03% | |
45 Neutral | C$12.90M | -1.99 | 64.52% | ― | 7.63% | -106.03% | |
45 Neutral | C$6.58M | -3.23 | 739.84% | ― | ― | -28.35% | |
44 Neutral | C$56.20M | -2.16 | -444.52% | ― | 415.06% | -54.80% | |
42 Neutral | C$11.23M | -3.24 | 6239.15% | ― | ― | 68.00% | |
41 Neutral | C$4.21M | -1.45 | 184.91% | ― | ― | 43.30% |
* General Sector Average
TSE:ADK
Diagnos
0.48
0.21
82.69%
TSE:AIDR
Rocket Doctor AI
0.58
-0.14
-19.44%
TSE:CHS
Comprehensive Healthcare Systems Inc
0.45
-0.05
-11.00%
TSE:UDOC
UniDoc Health Corp
0.13
-0.07
-35.00%
TSE:NARA
PanGenomic Health, Inc. Class A
0.30
-2.06
-87.29%
TSE:DMED
DiagnaMed Holdings Corp.
0.05
-0.04
-41.18%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.